Lever Bio, a biotech start-up active since early 2025 in the development of cancer therapies for tumour microenvironment reprogramming, announces that it has extended its seed round, which opened in April, reaching a total of over €9 million in funding.
The investment includes an additional subscription by existing investors Claris Ventures and Ora Global, and the entry of private investors from Club degli Investitori and Italian Angels for Growth.
The additional capital available will enable the company to conduct preclinical toxicology studies on one of the six programmes under development, with the aim of submitting an application to initiate a clinical trial by the end of 2027.
At the same time, the funding already raised supports the development of other assets in the pipeline, enhancing synergies and collaboration between the research groups that contributed to the scientific discoveries underlying the projects with Professors Massimiliano Mazzone of VIB-KU Leuven, Enrico Giraudo and Guido Serini of the FPO-IRCCS Oncology Institute, and Teresa Manzo of the University of Turin.
“We are thrilled by the confidence shown in us by private investor groups that are increasingly active in the biotech sector in Italy, as well as by the renewed support from our initial investors,” said Chiara Donini, head of scientific development at the company, in a statement (pictured). “The development platform we established in our first year of operation has already enabled us to nominate a first preclinical candidate, which we plan to test shortly in toxicological studies. Over the next year, using the same approach, we plan to identify up to three preclinical candidates for other programmes in our pipeline.”
ALL RIGHTS RESERVED ©